stent

Congreso SOLACI-SBHCI 2019

SOLACI-SBHCI 2019 | SOLACI’s Regional Sessions Say “Here!” at the Annual Meeting

For over ten years, SOLACI’s Regional Sessions have set trends in Latin America, promoting medical education, advancing scientific development and research, fostering interventionism’s best practices and organizing scientific events of utmost importance for our specialty in different countries across Latin America and the Caribbean. This is why both SOLACI and SBHCI regard the presence of<a href="https://solaci.org/en/2019/07/26/solaci-sbhci-2019-solacis-regional-sessions-say-here-at-the-annual-meeting/" title="Read more" >...</a>

Dietas bajas en carbohidratos y progresión de la calcificación coronaria

Calcium Scoring: “Location” Seems to Be More Important than “Percentage”

The presence of a high percentage of calcium in the left main coronary artery is independently associated with a 20–30% greater risk for cardiovascular and all-cause death in asymptomatic adults. This highlights the fact that calcium location, and not only amount, is important. Calcium scoring reports from computerized tomography (CT) usually inform only that: how<a href="https://solaci.org/en/2019/07/18/calcium-scoring-location-seems-to-be-more-important-than-percentage/" title="Read more" >...</a>

Clinical Implications of the New Hypertension Guidelines

Hypertension is the first modifiable risk factor affecting morbidity and mortality in nearly half of the adults in the US. The new ACC/AHA guidelines have issued new standards for the detection assessment and management of high blood pressure. The major change compared against their prior version was stage 1 hypertension definition, defined as systolic blood<a href="https://solaci.org/en/2019/07/18/clinical-implications-of-the-new-hypertension-guidelines/" title="Read more" >...</a>

Congreso SOLACI-SBHCI 2019

SOLACI-SBHCI 2019 Congress | International Joint Sessions

Prestigious Scientific Societies from all over the world will attend the Congress to discuss the latest advances in interventional cardiology. Discover the International Joint Sessions 01/08 | Paulista Room | 8:30 – 10:00 | Portuguese Society of Cardiology (APIC) Symposium – Acute Coronary Syndrome 8:30 – 8:42 – PCI in NSTEMI ACS: how and when<a href="https://solaci.org/en/2019/07/17/solaci-sbhci-2019-congress-international-joint-sessions/" title="Read more" >...</a>

Infarto agudo de miocardio y lesiones de múltiples niveles

New Promising Alternatives for Mitral Regurgitation

PASCAL transcatheter valve repair system for mitral regurgitation has shown feasibility and safety to treat patients with grade 3+ or 4+, regardless etiology. Regurgitation grade was significantly reduced, and this was accompanied by clinical improvement in functional class, exercise capacity and quality of life. This study soon to be published in J Am Coll Cardiol<a href="https://solaci.org/en/2019/07/15/new-promising-alternatives-for-mitral-regurgitation/" title="Read more" >...</a>

Peri-Procedural Infarction in Angioplasty vs. Surgery in the Left Main Coronary Artery

According to the EXCEL trial, peri-procedural infarction was more common after left main coronary artery surgery compared with angioplasty, and it was strongly associated with increased 3-year mortality after controlling all possible confounding variables. This increased mortality was only present in extensive infarctions with an increase in CK-MB ≥10×. The EXCEL trial seems to want<a href="https://solaci.org/en/2019/07/05/peri-procedural-infarction-in-angioplasty-vs-surgery-in-the-left-main-coronary-artery/" title="Read more" >...</a>

TAVI en insuficiencia aórtica pura, nuevos dispositivos con nuevos resultados

The FDA Affirms Mortality Signs with Paclitaxel Based Devices

Evidently, we are still uncertain. The information goes both ways, even on our own web page, we have been coming and going just like any other publication around the world. After a 2-day debate, the Circulatory System Devices FDA panel has confirmed the tendency to higher mortality with paclitaxel-based devices and is expected to debate<a href="https://solaci.org/en/2019/06/19/the-fda-affirms-mortality-signs-with-paclitaxel-based-devices/" title="Read more" >...</a>

Doble antiagregación: menos es más en añosos.

Cardiovascular Risk, Dual Antiplatelet Therapy, and Age. What Should We Know?

Non-adherence to dual antiplatelet therapy varies with age and patients older than 75 years old are those who discontinue treatment most frequently. However, this characteristic in elderly patients was not associated with more cardiovascular events. Treatment compliance protected patients younger than 75 years old from events, while there was increased cardiovascular risk among this population<a href="https://solaci.org/en/2019/06/12/cardiovascular-risk-dual-antiplatelet-therapy-and-age-what-should-we-know/" title="Read more" >...</a>

Lo más leído de mayo en solaci.org

The Most Read Articles of may in Interventional Cardiology

1- Surprising EXCEL Outcomes in Diabetics with Main Left Stenosis This study especially designed to compare PCI vs. CABG in patients with left main coronary artery disease and low to intermediate Syntax score showed that 30-day and 3 -year outcomes of PCI with everolimus eluting stents vs CABG were consistent both in diabetic and non-diabetic<a href="https://solaci.org/en/2019/06/06/the-most-read-articles-of-may-in-interventional-cardiology/" title="Read more" >...</a>

Efecto a largo plazo de los balones liberadores con bajas dosis de paclitaxel

Mortality and Paclitaxel Devices, Data Are Aligning

5 years ago, several prospective randomized studies confirmed paclitaxel coated balloons were safe and effective in femoropopliteal territory. However, a recently published meta-analysis of heterogeneous studies including both paclitaxel coated balloons and drug eluting stents has linked these devices to mortality. In addition, higher doses were associated to higher mortality, both at 2 and 5<a href="https://solaci.org/en/2019/06/05/mortality-and-paclitaxel-devices-data-are-aligning/" title="Read more" >...</a>

Top